YONGIN, South Korea--(BUSINESS WIRE)--GC Labs (CEO, Dr. Eun-hee Lee), the leading clinical diagnostics company in Korea, today announced the new lab testing service agreement with two partners: Bio ...
Tests do not consistently influence risk classification or treatment decisions; authors call for well-designed trials on role of GC tests in newly diagnosed PCa. (HealthDay News) — For patients with ...
Genomic classifiers (GC) have been shown to improve risk stratification post prostatectomy. However, their clinical benefit has not been prospectively demonstrated. We sought to determine the impact ...
Genomic classifier (GC) tests do not appear to consistently influence risk classification or treatment decisions for patients with newly diagnosed prostate cancer considering first-line treatment, ...
A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...
For patients with localized prostate cancer (PCa), tissue-based genomic classifiers (GCs) do not consistently influence risk classification or treatment decisions, according to a review published in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results